These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    Author: James JS.
    Journal: AIDS Treat News; 1995 Dec 22; (no 237):3. PubMed ID: 11363075.
    Abstract:
    ACTG 320, a nationwide trial, will compare the triple combination therapy, indinavir plus AZT plus 3TC (lamivudine), to the double combination therapy of AZT plus 3TC. The trial is expected to start in January 1996 and to last one year. Patients must have CD4 count under 200, have tolerated use of AZT for at least six months, and be 3TC naive. Every participant will receive AZT plus 3TC, with some also receiving the protease inhibitor. The trial is being run by the AIDS Clinical Trials Group, with funding from Merck.
    [Abstract] [Full Text] [Related] [New Search]